Medinex Ltd. (OTX) AI Stock Analysis

• Market Cap: S$30.95M
• Dividend Yield: 7.3%
• Average Volume (3M): 102.58K
• Price to Earnings (P/E): 9.3
• Beta (1Y): -0.06
• Revenue Growth: -2.08%
• EPS Growth: 129.31%
• Country: SG
• Employees: 73
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.02
• Shares Outstanding: 134,543,840
• 10 Day Avg. Volume: 45,910
• 30 Day Avg. Volume: 102,580
• PEG Ratio: 0.05
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 2.05
• P/FCF Ratio: 7.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 77 Outperform
• Price Target: S$0.26 ▲(8.75% Upside)
• Action: Reiterated Date: 03/24/26
• Date: Action: Reiterated 03/24/26

The score is driven primarily by strong financial performance (high margins, low leverage, and solid cash conversion) and supportive valuation (low P/E and high dividend yield). This is tempered by mixed/neutral technical signals, including slightly negative MACD and prices sitting near moving averages.

Positive Factors

Revenue Growth

The consistent revenue growth reflects the company's expanding market presence and successful product adoption, supporting long-term business sustainability.

Cash Generation

Strong cash generation enhances financial flexibility, allowing for reinvestment in innovation and expansion, crucial for sustaining competitive advantage.

Profitability

High profitability margins indicate efficient cost management and operational efficiency, supporting long-term financial health and shareholder value.

Negative Factors

Market Saturation Risk

Operating in a niche market could limit growth opportunities if market saturation occurs, potentially impacting long-term revenue expansion.

Employee Base

A relatively small workforce may limit the company's ability to scale operations quickly, potentially hindering its ability to capitalize on growth opportunities.

Dependence on Partnerships

Heavy reliance on partnerships for growth could pose risks if these alliances weaken, affecting product development and market expansion efforts.

Medinex Ltd. Business Overview & Revenue Model

Company Description

Medinex Limited, an investment holding company, provides professional support services to medical clinics in Singapore. It operates through four segments: Medical Support Services, Business Support Services, Pharmaceutical Services, and Medical Services. The company engages in the setting up of clinics, facilitating applications for relevant clinic licenses, value added services to healthcare sectors, turnkey solutions, as well as strategic advice to general practitioners and specialists on establishing clinic facilities. It also provides accounting and tax agent, human resource management, and corporate secretarial services, as well as business support services, such as accounting, tax agent, human resource management, and corporate secretarial services to various sectors, such as food and beverage, retail, education, and beauty. In addition, the company procures medical and pharmaceutical products to clinics. Further, the company offers diagnostic and x-rays, pre-employment check-ups, vaccination, customized healthcare plans, and health screening services in clinics. Additionally, it provides advisory services, and business and management consultancy services, call support services, and data protection officer services to its customers; and training services. Medinex Limited was incorporated in 2009 and is headquartered in Singapore.

Medinex Ltd. Financial Statement Overview

Summary

Strong overall fundamentals supported by high 2025 margins (gross ~77%, net ~22%), conservative leverage (debt-to-equity ~0.10), and solid cash conversion (operating cash flow ~1.04x net income; free cash flow ~0.99x). The main risk is year-to-year volatility in revenue growth and profitability, making sustainability of the 2025 rebound important.

Income Statement

Profitability is strong for the industry, with 2025 annual gross margin around 77% and net margin around 22%, showing a sharp rebound from 2024’s weaker net margin (~8%). Revenue growth in 2025 was positive (~15%) after a slight decline in 2024, but the multi-year trend shows uneven top-line momentum (notably a large drop in 2021 and a surge in 2020). Overall, margins are attractive, but earnings and growth have shown volatility year-to-year.

Balance Sheet

Leverage looks conservative, with debt-to-equity improving to ~0.10 in 2025 (down from ~0.13–0.24 in prior years), providing balance-sheet flexibility. Equity has been steadily built and remains sizable relative to total debt, supporting resilience. Return on equity improved to ~17% in 2025 (vs. ~6% in 2024), but the variability in returns suggests profitability can fluctuate and should be monitored.

Cash Flow

Cash generation is solid and high-quality: 2025 operating cash flow slightly exceeded net income (~1.04x), and free cash flow was roughly in line with earnings (~0.99x), indicating profits are translating into cash. Free cash flow growth accelerated strongly in 2025 after a decline in 2024, pointing to improved cash efficiency, though the growth rate has been choppy across years.

Breakdown	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2021
Income Statement
Total Revenue	12.81M	12.58M	12.97M	11.99M	10.79M
Gross Profit	9.93M	9.68M	9.48M	8.57M	3.31M
EBITDA	3.58M	1.79M	2.88M	4.00M	1.69M
Net Income	2.83M	1.03M	1.70M	2.81M	3.49M
Balance Sheet
Total Assets	20.69M	20.50M	22.59M	22.98M	23.43M
Cash, Cash Equivalents and Short-Term Investments	5.56M	5.17M	4.15M	6.34M	6.73M
Total Debt	1.67M	2.08M	2.34M	3.10M	3.95M
Total Liabilities	3.96M	4.34M	4.81M	5.51M	6.50M
Stockholders Equity	16.72M	16.12M	17.57M	17.25M	16.66M
Cash Flow
Free Cash Flow	3.33M	2.67M	2.83M	2.63M	2.96M
Operating Cash Flow	3.35M	2.70M	3.03M	2.86M	3.04M
Investing Cash Flow	243.45K	1.66M	-2.19M	-16.91K	-2.61M
Financing Cash Flow	-3.20M	-3.33M	-3.02M	-3.16M	748.53K

Medinex Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:OTX, the sentiment is Positive. The current price of 0.24 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.23, and above the 200-day MA of 0.22, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.12 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:OTX.

Medinex Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OTX	77 Outperform	S$30.95M	9.27	20.77%	7.30%	-2.08%	129.31%
1B1	74 Outperform	S$54.60M	5.19	34.20%	3.37%	1.58%	115.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%